What are you looking for?

Surge Biswas is a co-founder the CEO at Nabla Bio. He received his PhD from George Church’s lab at Harvard, where he developed the first protein language models. Outside of Nabla, Surge enjoys hanging out with his wife and Nabla co-founder, Frances, and their two dogs, Archie and Riley.

We present JAM-2, a fully computational antibody design method that produces VHH-Fc and full-length mAbs with drug-like affinity and developability. Across 16 unseen targets and in under a month, the JAM-2 achieved 100% target coverage with double-digit percent bind rates and frequent picomolar to single-digit nanomolar binders from just tens of designs tested. JAM-2 also directly generated GPCR-targeting antibodies in native cellular contexts, delivering lead-quality molecules without post-hoc optimization.